VKTX - Earnings call transcript Q3 2019 | Viking Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Viking Therapeutics 2019 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Following management’s prepared remarks, we will hold a Q&A session. [Operator Instructions] As a reminder, this conference call is being recorded today November 5, 2019.

I would now like to turn the conference over to Viking’s Manager of Investor Relations, Stephanie Diaz. Stephanie. ahead, go Please

Stephanie Diaz

you participating thank today’s all and in for call. Hello

Viking’s today of CEO; is me President Finance Brian Administration. President Joining Vice Lian, and Morneau, and and Michael

during like and will the XXXX, forward-looking Company, beliefs number of statements of a that begin, XXXX November meaning contain to of the which Securities we call today, involve I’d comments Before assumptions, of made the this within concerning conference X, current caution risks you Act the results the revise Company’s Actual and all and could concerning and Securities obligation statement these statements, Exchange of the undertakes differ to these Company uncertainties. other or made from no today. to the any update matters. with Commission I filings encourage review

turn his call Lian the Brian to initial Brian? now for over I comments. will

Brian Lian

Stephanie, progress developments well everyone thanks Today, financial will on provide or third operations. and webcast an overview as our to update results, we the and quarter by of related recent our to phone. an pipeline programs as and Thanks, listening on

toxicity agonist in required this beta initiation with NASH. novel the Phase third be During will key that respect patients for milestones biopsy-confirmed chronic laid included beyond. and Xb completing long-term company VKXXXX, planned groundwork receptor dosing preparing our for studies XXXX humans the believe of With to the our Viking for for and value we trial in drivers important quarter, the thyroid the in

we a commence continued X-linked X our the in second expect work proof-of-concept VKXXXX, to beta which initiate XXXX. half during of in or quarter, respect receptor Phase X-ALD, to adrenoleukodystrophy, first the With agonist, the required to thyroid we study

our first, to on a activities detail in results. few development review minutes, financial we’d but I quarter will provide additional like third our

Finance I’ll now to financial results. President over Mike? call Morneau, Administration of Mike turn discuss Vice to and our Viking’s the

Michael Morneau

results expect to Viking’s Securities to XX-Q ended Exchange Commission, I’d participants filing with we In and recommend comments, now which and quarter for none details. go the today, XXXX. like Brian. additional Thanks, the the third with conjunction months I’ll that for financial file XX, my later refer to September over

development three the by XX, million, in The and due partially million same research months for period Our expenses ended stock-based XXXX for XXXX. third-party in consultants. an in to increased related the were $X.X clinical provided to were compensation, studies, decrease candidates, and drug September to in compared decreases and through manufacturing services primarily offset by preclinical $X.X expenses our expenses

and XX, salaries were general to fees, services to compensation, expenses partially in increase third-party XXXX Our administrative and three to due compared same offset consultants related and decrease in by period provided $X.X $X.X was million million, for for expenses in stock-based ended September the a increased The months the primarily by expenses professional XXXX. benefits.

Viking XX, three to the XXXX, in of compared months share, For million per September loss $X.X net reported a loss share in or $X.XX a of million $X.XX XXXX. corresponding period the per $X.X ended or net

third due XXXX. primarily months loss same decrease The income in September recorded an recorded per to loss for XXXX the in share the period in was XXXX net XX, quarter versus three in net of increase and of ended that the interest

by partially to was million, primarily XXXX. The expenses manufacturing ended XX, in preclinical in period nine third-party offset to candidates, for for due development September XXXX $XX benefits, and clinical for decrease our services increased $XX.X and research provided the consultants million studies, related Our to same salaries drug months were a expenses studies. to in by the increase and compared expenses

consultants stock-based same million primarily compensation, expenses $X.X fees. million, increase to September third-party ended in due the in and to compared was XX, and the for general by XXXX The administrative professional expenses period for increased Our $X.X nine XXXX. services were provided months

the nine increase $XX.X XX, in to and $XX.X or the and to conversion of Viking related for the in partially ended The net the Note nine future $X.XX net or share, loss September $X.XX an period due compared was in million in the net September in increase months May the to debt previously, loss value as of change For a the the XXXX, reported a in repayment offset expenses Ligand ended administrative an noted research by elimination XXXX primarily XXXX. the million development months per of and of increase per as due income interest of fair loss XX, expenses XXXX. in general corresponding liability well to share

in per XXXX. decrease the XXXX, was months net outstanding versus primarily XXXX outstanding additional weighted XXXX given at average XX, XX, XX, September shares equity September in ended loss average weighted by nine The share September occurred at the public those shares financings for that the driven

million had balance Viking XXXX, stock Turning of the investments of and to $XXX.X XXXX, had XX, sheet, cash, XX, XX,XXX,XXX and October at totaling we cash outstanding. common as equivalents September shares

This concludes the and turn I’ll my now back to over review Brian. financial call

Brian Lian

Thanks Mike.

the the Xb of we VKXXXX the NASH. believe in facilitate achievement will for call, we or work third biopsy-confirmed were of key important progress made patients in with study stated preparing quarter, our first Steatohepatitis during planned focused milestones. the non-alcoholic that beginning of the I discuss corporate As at Phase I’ll on completing

is from small receptor potential beta therapeutic receptor VKXXXX range NASH. hormone of suggesting subtype agonist as including disorders an of as molecule tissue thyroid reminder, liver a the in a the the promising As possess well lipid that orally-available, selectivity

of with receive VKXXXX mg every in Participants VKXXXX, September of disease. non-alcoholic daily, mg XX were and XX results or daily, XXXX, weeks. day for from liver fatty study randomized In placebo announced to patients this X doses positive mg of X we other XX hypercholesterolemia Phase a in trial

trial liver in demonstrating were endpoints well in content, its both reductions achieved measures. We to plasma the as and as primary pleased that potent report fat secondary improvements lipid

year, reductions LDL statistically compared cholesterol, this and EASL patients. with placebo-treated reported with we respect the VKXXXX-treated demonstrated at endpoint, As primary at to in significant year trial’s AASLD patients last

VKXXXX-treated and In triglycerides other proteins significant including addition, experienced patients atherogenic apolipoprotein improvements lipoprotein statistically the (a). lipids in and B

reductions secondary key VKXXXX-treated patients fat endpoint, the MRI-PDFF. to assessed respect by in as experienced significant With liver

mg median Specifically, patients relative a receiving fat of dosed from baseline. liver content at X reduction in XX daily for XX% weeks VKXXXX approximately experienced

XX fat approximately other approximately doses median doses Across relative experienced VKXXXX reduction baseline median from a approximately day VKXXXX all relative daily of reduction XX% XX%. receiving mg median VKXXXX from patients mg experienced liver cohorts, every receiving Patients was fat relative in liver baseline. a in reduction of XX% liver reduction of the fat of XX and

liver a X%. placebo receiving patients reduction fat comparison, approximately By experienced median of in relative

which studies overall a liver identify increased relative probability reduction to experienced fat fat who intended demonstrated of a a liver also important histology. was or is an correlates XX% or included responder This patients threshold trial of greater XX% that multiple have content. The an improved with as analysis, reduction in more

positive. XX% this of at other fat patients VKXXXX VKXXXX results dosed in at reduction patients of dosed a experienced were liver analysis reduction daily in The XX% at All content. with liver mg demonstrated least day fat. X XX least every receiving a Approximately treated XX% at mg

VKXXXX patients in in placebo receiving doses XX% response. experienced liver of for treated a all approximately cohorts By study XX reduction comparison, demonstrated least this rate approximately day, per across at was XX% a fat. And XX% with The of XX%. responder mg patients VKXXXX approximately

candidates and multiple in many we the treat drug is the In in last readouts data unmatched the observed rate in announced believe currently development oral to NASH by any developments. currently to response other year, VKXXXX considering compound

events an distributed also the safety In the placebo serious demonstrated adverse arms. observed, adverse encouraging efficacy robust receiving X has and profile. evenly tolerability patients addition of VKXXXX treatment to VKXXXX reported overall Phase were numbers across relatively among were In the study, no events or and

many unique developments. liver benefits to other a of factor providing global when health differentiating We systemic potential compared lipids VKXXXX’s improve agents currently in believe also key through reductions is while cardiovascular to

For is believe NASH the clinic. it the most to candidate VKXXXX be promising treatment for in advancing and are through the of these today we excited we development reasons,

report VKXXXX an Products. we this the application are to of our forward that To we filed of recently move continue FDA’s development we Errors IND Inborn and end, pleased aggressively and Gastroenterology to with Division with

conducting We biopsy-confirmed Xb NASH. Phase required on are up planned currently ramp for focused in with the patients activities study important our

fully preparing facilitate and are to sites initiate study the our quarter. in smooth order study supplying in we a to clinical and this currently plan Today, engaged We training, efficient initiation.

FX As VKXXXX, of fibrosis, we a trial previously and described, have well for as up to fibrosis. with and planned dose the months FX expect than as we number patients limited evaluate FX with one XX to enroll to more

study detail trial We on when design will is initiated. provide the more

therapeutic proved X-ALD, I’ll an is for evaluated being program. disease X-linked for there no which VKXXXX provide update is on as treatment potential a or our VKXXXX devastating a adrenoleukodystrophy now treatment.

can by toxicities caused that accumulation and the defect very This are fatty these peroxisomal contribute result acid in it an long called tissue elevated acids is and fatty of and characteristic long motor ABCDX. that the severe very neuron to to chain the chain disease. X-ALD in is are in cerebral transporter believed of levels a plasma defect

receptor important chain a therapeutic for very an metabolism. thyroid in fatty intervention is The long acid is a regulator, beta target known X-ALD, potential it because

fatty significant is and of subtype. in have in both acids selectivity the that very potentially VKXXXX the administration plasma agonist in tissue orally results vitro long for studies available benefit. thyroid an of from vivo reduction a Like results receptor leading chain molecule possess in that therapeutic small VKXXXX, a beta To-date, and demonstrated receptor to VKXXXX

centers. achieved program collaboration are with our of this the to excited the research X-ALD Krieger for Krieger Viking Institute, and advance promising Both findings world's and to-date our teams through were VKXXXX Institute clinics. leading the Kennedy These eager one ongoing Kennedy results into the by

study conducting in for initiate are and of XXXX. the plan to work the VKXXXX in We a IND-enabling currently humans first half proof-of-concept

matters, both we to VKXXXX clinic, carefully as the resources. it to important our continue we corporate to is simultaneously advance note VKXXXX financial that through manage Turning and

multiple remain X-ALD. quarter result, we completed VKXXXX in in in a to equivalents. approximately points studies proof-of-concept including and third the We with of VKXXXX NASH, inflection cash million confident of allow $XXX with as studies funds these completion are as sufficient clinical well As

to In during humans. respect has quarter work conducted for ahead. toxicity in With conclusion, dosing to studies readied the we third us that long-term support the milestones lie the completed recently clinical chronic VKXXXX, considerable

recently remain basis application planned our of by Phase filed was clinical with results clinical NASH and an non-clinical track year of with the in FDA. along end. IND that initiate the on trial to studies, data Xb We biopsy-confirmed The these forms additional

IND-enabling VKXXXX, we the to on this work continued X remain year. Phase we in the in of proof-of-concept track respect to begin and that X-ALD conduct With to allow half next us trial will to first a study initiate

will believe earlier developments as maintained through on our we Finally, other as a our carefully programs, support including studies. see we updates and planned balance are key company pipeline available. spending well clinical to continue look the have programs stage the our milestones they providing of forward to as and sheet corporate strong advancement these, We manage that to

This like prepared comments us for today. again concludes to questions. our Operator? for now Thanks call open the I’d for and joining

Operator

go with [Operator Seedhouse Steve first question Raymond from James. Instructions] Our comes Please ahead.

Timur Ivannikov

Yes, Steve hi. Ivannikov IND Timur filing. This your for on Seedhouse. Congratulations is on

So, you considerations that you had for about your we Xb to the FDA design. talk Phase Could study important the a are about waiting confirm? question most

For need only for to prior. versus three XX think example, I run you months permission months

no you design to for wide win I of So you. the good would have you it range. consider restrictions and Thank would severe like type confirmation be FDA Viking? dose also a from and what to a guess, a test will

Brian Lian

thanks, Timur. Okay,

here said of features. that initiation. study Type patients We will be of we term sorts the what details X of and be longer those at would trial the able say would than enroll a to hope again design three with and is past certainly So, what the diabetes I’ll months we disclosing and we in for time plan the to

say when trial are going to, call. So, that details, to this we we to we but design of give going lot are to able lot of we details make will on are have on not not more a a

Timur Ivannikov

amount could study, Okay. centers activities then, your manufacturer And Thank terms bit you am preparation to potential contracting with in you I to manufacture guess, for your little this talk for clinical VKXXXX of about And have I talk kind and Phase investigators? your they dialogue Phase Xb, had more a Thanks, about the the you the Xb could Brian. had – of sure supply study if not before? you. readiness of

Brian Lian

question. Yes, thanks. a It’s good

embarking company, any like – we So, study. a larger on

will trial time initiate be multiple planning open I forward have is we We study and those the would that sites initiated processes all when be been the for think, quite to expect are of for expected some and as moving enrollment.

There real update no on is manufacturing.

to prepared fully are not We that’s issue. study supply an the

we getting now, forward looking right started. are to so, And

Timur Ivannikov

much. very Thanks Okay.

Brian Lian

Thanks.

Operator

Our SunTrust. go ahead. next Please Joon from question Lee with comes

Joon Lee

my Hi, the of question thanks taking for IND. submission and

your So, you And cash I ramp is as noticed clinical from yearend prior expect sites? untouched cash guidance? basically the in a you What’s your trial quarter. cash spend open do when

Michael Morneau

Thanks, Joon.

quarter. So, the and robust. tick pretty bit in cash the But I fourth ticked down it up think has the in XXXX. a little in quarter It remained, will

it than three was guidance, quarters say, it will year. any be the I materially but given would first higher haven’t of We in this –

Joon Lee

you the to wait of assume the that Is get first fair And regarding it design, until Phase compares trial? or very NASH provide able color to to to we or Xb the the studies? able is should extent enrolled to insidings say and – it’s are IND actually the how patient you that are trial to to any line it the other Or similar?

Brian Lian

It’s question, a Joon. good

as that MRI, earlier I So, are for Xb later. at we’ve maybe Phase bit bit other relevant used little studies a the looking a and little histology a think us template,

And forth so, we would template. that we be all when But will and parameters the able start. have the on to that are so the of endpoints

with competitors You’ve seen it longer-term couple of histology then later. an a MRI interim that and study in a our

Joon Lee

differences this point, for? fair And believe are are criteria also to or that that at that enrollment assume is there to but wait similar should we it the

Brian Lian

would NASH that we Yes. we for for to But, populations exclusion everybody will more. Xb is inclusion, question Phase This have enroll a other key I the yes, little it Once studies. we to think intend the study, we a bit similar and discuss initiate criteria. will

Joon Lee

And would first a press the Excellent. when release, then, PR lastly start study is the you having you enrolled? patient

Brian Lian

press we a study, release yes. We the when have start will

Joon Lee

so Perfect. you much. Thank

Brian Lian

Thanks.

Operator

Our Archila ahead. go next question comes from with Derek Stifel. Please

Unidentified Analyst

This Hey. [Ph\ Derek. is Evan for on Thanks guys.

to or Just Xb going Thanks. be is U.S. both? wondering if ex the U.S., Phase

Brian Lian

thanks. Yes,

So, right now, it’s primarily U.S.

initial to other preparing countries, move We but into will be primarily will the be study U.S.

Unidentified Analyst

Okay. Thanks.

Brian Lian

you. Thank

Operator

Olson from Our Jay with Oppenheimer. ahead. next Please go question comes

Jay Olson

on this and Congrats quarter taking for Brian. the questions. Hey, all thanks the progress

Brian Lian

you. Thank

Jay Olson

you Can to gastro question. division? division the you the with IND with had And then the please filed I between the the explain you differences key filed just previous IND metabolic follow-up compared

Brian Lian

the really prior the for IND IND, cleared with the this compound was XX question, in the metabolic is protocol prior the utilized in hypercholesterolemia. had great owner it so study of that prior FDA week a a the the – Yes, a division or study

measures endpoints And the so, we as took NASH, to liver well that as that study and of were fat content, enrollment relevant added the like certain adjusting criteria.

patients related we The current primarily IND biopsy-confirmed is quite a are lipids. bit different. endpoints at NASH. liver where will looking It’s with plasma to targeting be The the

And into IND. this lot importantly, data more went a

XX So, IND prior the the week tox. was

as the from substantially completed here, have well as study. the data tox We obviously more X data Phase

a completely lot So, in data a IND more in protocol. different this

Jay Olson

up profiles in? the the just with very how That’s Great. agonists? profiles between the plan Thank you. them question, talk can as of a indications line you And study two And to those differences beta key different thyroid helpful. then, you follow-up your about two

Brian Lian

for structures NASH. think the cleaved a by prodrug the in molecule and that bit has and thought a liver-directed – not told, relevant different probably suitable a that more is X-ALD liver moiety are a key be we difference to pretty It’s chemical that’s Yes, both diffused. XXXX little is prodrug compounds the CYPXAX, so we molecule more that might XXXX

the a and in single-digit But for really mover bit receptor. was bit beta a looked over KI the XXXX different. PD profile selectivity the that still It’s animal It’s the promising just on nano little X-ALD. really, got for studies, the alpha receptor little better

characteristics slightly slightly are the a solubility different. It’s characteristics, biological different

metrics. just different molecules profile different So slightly got that’s on that’s those

Jay Olson

and congrats additional color the for the progress. on Thanks Great.

Brian Lian

Jay. Thanks,

Operator

go Bautz comes Zacks Our Small next Please Cap from David with question Research. ahead.

David Bautz

morning, good Brian. Hey,

Brian Lian

David. Hey,

David Bautz

large back could I XX am to presumably quantify any the curious the could recently that if to more there able take it? days that on IND you get this chance than filed? how you are filing you is, with get And is to FDA is

Brian Lian

key the details timing. not are going a we to and it’s give Yes, any around question

your the You don’t larger point. raised IND. a good impacts IND size I’d time, it’s point a the review quite Whether know. bit than really interesting say, that But is, typical a we this of that

David Bautz

it Okay. partner XXXX, data necessary before think do And you ready as in? to far partnering is will biopsy-confirmed to come potentially a as have be

Brian Lian

better no. partners. a my So, is, feeling potential But question for

I we’d a histology see that like think we’ve to others stage activity seem less the that seen past on lines, data. but we data, in of along those was But earlier that some made are as comments of be hurdle. hear maybe holding to the

think white a the – depends all But don’t it’s it’s I gating don’t and factor. it a on So I partner. black gating think

David Bautz

you monotherapy? about hear more more interested, maybe Or are And combination a therapy? it interest do using as a partners Okay. as of think in do XXXX part you

Brian Lian

the depends on other party. it again, Yes,

maybe there little it the for a and I everybody direction is what But certainly mean, time, quite does like than together for not is say, agents. I partnering might to think, I it are a it’s some has play drifting in everybody. more some ago. feels a think that about shift satisfied like, interest and bit more the well single with been it heavily combination feel mechanisms this little year talking was, therapies

David Bautz

for the Okay, questions. taking great. Thanks

Brian Lian

David. thanks, Yes,

Operator

question ahead. Andy Blair. with comes Hsieh William Please from next Our go

Andy Hsieh

taking my Congratulations the question. Great. thanks on progress and for

So, one progression. related I have is to that disease

in than in view So, have on for or patients what’s not liver XX% but who fat, going you benefit do even subsequently a XX% patients? did these experience reduction greater histologically, about

Brian Lian

histologic benefit. is like, at a probability published It see you But you higher don’t XXX%. a the it’s conferences, This Yes. not these when at analyses presentations is and look know. great question. seems will I that

patients doesn’t fat better But hold or that some related know. to that and everybody larger histologic underlying predisposition, that it maybe responses and greater true XX% reduction. seems who just don’t genetic have you for in see histologic responses It is I liver

Andy Hsieh

by question, seems this strategic in like, approval curious market about efforts China guess, week drugs earlier potentially the it a reform given Viking And I and Alzheimer’s Okay. was your very surprised China approval. there, regarding drug I the get for am thoughts I the so, could conditional

then, if world seems need database or larger efficacy, like rely patient a on you they real safety And it data.

provides rapid strategy. really with a it you to market So

your wondering Just thoughts there. about

Brian Lian

interest bit interesting there, an that allows little from – do well more of a I that’s is constructive in philosophy and China is and everybody of we disease that in that a to offset do Andy. a field This more population Thanks, taken to different I’d get Yes. say, features we so, parties the sure maybe maybe you am differences does, tends point your forward inbound move is little by question, more easily. the skinny NASH. the bit Asian regularly

proof-of-concept So but in study not It’s registration. that consolatory, in step population likely path. run and regulatory little more that is you I different NASH think population that huge the to that a potentially it the to it offset getting a does prior and a to would require back difference,

But, we conversations if some always we partners to decide ongoing let do certainly you and to we we to have know. those talking are open and do will anything,

Andy Hsieh

I again. Okay. Congratulations That’s all have.

Brian Lian

Andy. Thanks,

Operator

question with from & comes ahead. Please next go Laidlaw Our Company. Yale Jen

Yale Jen

in and thanks taking I early Good morning now. quite the and for it’s questions your time know

ones. quick two Just

you obese also obese the one know Or issue? but time one as include how is particular talked of details, study. much about patients think that last the about I Phase for – have would the you First patient do you Xb possibility?

Brian Lian

into I to think restriction the MRI machine. fit obesity is Yes, the only on ability the

unexpected unless enroll is So expect to obese there. we some patients would limitation there

Yale Jen

know. to increase good across little aspects your maybe as quarter Would will mentioned is a that then, the in be assume fourth basically the will what that which that just be I housekeeping last other of And R&D you question, or more side a sort any substantially. well? That’s Okay. expense change

Brian Lian

it would exclusively on be Yes, R&D almost the side.

Yale Jen

and congrats so far. progress And Great. thanks Okay. for the

Brian Lian

Yale. Thanks,

Operator

go Sarraf ahead. Our from with Leerink. next SVB question Please comes Pasha

Mike Kratky

acceptance have this Pasha. my taking to that, this study? it it if earlier. Xb confirm will of for of for release a Hi, going press the FDA really just on know is note just But is Mike that for IND? Thanks you be to you’ve on start touched question. Or Brian, the that you wanted I Phase

Brian Lian

relatively there difference So, that I think be will minor. the

it hope with So, have we very which on will concurrent we the to be initiation clearance. nearly would the

Mike Kratky

Got that get Xb study? you’d that are what about the it. based question, thinking study what of about know second a the But the curious on confirmation. Phase dosing FDA you And pursue design in That you’ll Xb versus for you once talk says? ones then, just you’d makes just sense. the I doses terms more in pursuing are like confident you be to additional any Phase how

Brian Lian

as some all and because in said always that overlap of to Xa well, that study would Phase sort efficacy. will there we’ve it from lower be also similar study, so, were cohorts we the Yes, like three in then explore looks like doses

the of the They are just end sort dose on of far clustered response curve.

purposes. So, attractive down we efficacy. come realize, think and comparative study overlap do think we But have for I with pretty can we want still that some to

Mike Kratky

Thanks Okay. much. very

Brian Lian

Thanks, a lot.

Operator

next go with Our FBR. from Mayank comes Please B.Riley question ahead. Mamtani

Unidentified Analyst

This Mayank taking for Brian. on for is questions. Hi, you my thank and Wayne

So, the the your are Phase question your learnings on I Xb first NASH design, FDA in dialogue stands the what definition? is, resolution on acceptable with have

meetings. to in seems define another level may way we there the upcoming like have Because

do the for efficacy you So to in definition intend which determining the with advance VKXXXX?

Brian Lian

said those Xbs and – the registration, will endpoints we’ll in endpoints, as I of think, – studies of other I been and of similar include I reported different think all response registration that question, be the as registration subsets design another endpoints. of have Yes, pretty as the Phase these most to to well both to

more be promising to of two registration the We no We’d for are want different. understand compound. which the certainly endpoints

Unidentified Analyst

one the level study. observed study as there dose Phase in the you on this to had how think you’d that forward? AFLD weather, you perspectives Are do Okay. in and observed how have FDA X well may other the toxicity perceives as window inform the take why chronic this any preclinical the Thanks. elect And is, you your

Brian Lian

see on could reason what we planned that the realize We probably in any think exposures. higher, but the we selected didn’t saw X. we lower dose at doses Phase did to based We efficacy

adequate have side move that the think, I forward. to all allow doses and animal our on tox planned thinking. the the coverage But, we side maybe toxicity of to was

Unidentified Analyst

progress. Thank Okay. the questions taking on for you the and congrats

Brian Lian

Okay. you. Thank

Operator

from ahead. Wainwright. question with Please Joe comes Pantginis go H.C. next Our

Joe Pantginis

Hi guys. I’ll morning. tox encouraged get Thanks for want saying, question. this Good companies the you tox. by details assume in on did But for focus taking term preface that don’t kinds general. one these the obviously we see could are Brian, the I what to from of by question a second. for longer Obviously, you

the curious be was Anything would is tox? with you I helpful. Thanks. just stuck that you pretty point vanilla longer are with it provide there that out, anything Was so, that term could anything You pleased can to? details.

Brian Lian

Thanks, well. question our comments and it’s and consistent to industry detail. pretty give Joe key are know I a with not I standards we a prior the and going as really obviously with it’s know of lot

in I studies. think the are we comfortable term longer we that observed with what have

We have just, far, going I so be the give do okay in detail a what the we completed. lot are But, see. But, more appreciate not to there. not But we interest I with question. think, able the to final analyses

Joe Pantginis

No, understand. you. Thank I

Brian Lian

Thanks, Joe.

Operator

comes next ahead. Roth Scott go from Capital. [Operator Instructions] Our question with Please Henry

Scott Henry

morning. good Thank you, and

we get may at XXXX, With data questions. first there very look a I our any just of Just when form? a for get couple quick any am trying in interim And expectations sense data? the to are

Brian Lian

It’s Yes, point. important an Scott.

the look at some the Xb that if at prior as of look – do we to is MRI you follow we that playbook studies MRI histology dataset prior So, data made available early, and Phase hope well. to that

Scott Henry

that sense and enrolling enrolls any do may trial see have track? starts the when kind of on And you of Okay. we assuming

Brian Lian

Yes, it’s now. right to hard predict

get see we our looks enrollment before to think making the what study into I like want a a ways versus little prediction. projections and

Scott Henry

Okay. enough. Fair

I expect we second event? to, know Or guess, of XXXX if first proof-of-concept X-ALD. in on color do just The to IND early you trial? in an be the can I file how first, with any – don’t that will that kind question, regards you to expect And what for it and give should QX?

Brian Lian

that adaptive what ascending dose when where of going a in you and then kind likely initiate healthy to we’ve ascending the the healthy design be indicated XXXX dose is, it volunteers with volunteers. past in into in it’s roll study be a IND Yes, will seamless we file a in multiple and single

short-term into proof-of-concept in then, roll And patients. study a

hope in have And a preliminary so, results goes position we toward well. would next if of to all to be some end year, the

Scott Henry

Thank for you Great. Okay. questions. taking the

Brian Lian

Thanks, Scott.

Operator

question McCarthy ahead. go next comes Jason Our with Maxim Group. from Please

Jason McCarthy

Hi, the XXXX. on to keep Brian. taking going questions. I was Thanks for

a from drug can As a activity been the company because around space, clinical the looks to really it’s portfolio, historically. development diversify bit talk you little about difficult adrenoleukodystrophy the perspective very a

that and these could been with activity has you lot discuss But each there how involved therapy it’s different, ABCDX. And two and/or complementary other? approaches the maybe But on of gene could even be side to targeting ABCDX. unique XXXX is clearly

Brian Lian

Jason. Yes, thanks,

progressive, targeted So, the likely The the disease. we adrenomyeloneuropathy the fatal population. that’s form form - of would anyway gene disease the is target often the rapidly adult of therapies the typically initially XXXX population the with and cerebral which childhood have

gene so during We the you expression therapies in while gene period is could and that particularly the ameliorate where chain complement that to then think of therapies, ABCDX acids takeover. to the XXXX it engraftment natural taking fatty very sort we the will speak, expect should – long hold, elevations because get

promising we in that XXXX the population, being particularly and there. aren’t think is therapies the pursued gene adult actively as But

initial our be would that So, focus.

Jason McCarthy

Thank you. great. Okay,

Brian Lian

Thanks, Jason.

Operator

session. closing back to question-and-answer remarks. our would concludes turn like conference over This the for any I to Diaz Stephanie

Stephanie Diaz

great coming continued Viking again in support you the of participation for We your look to again Therapeutics. Thank updating you Have day. and forward months. a

Operator

for The presentation. conference you is attending today's concluded. now Thank

You may disconnect. now

Viking Therapeutics (VKTX) 5 Nov 192019 Q3 Earnings call transcript